Edwards Lifesciences Corp
EW80.500USD
0.0000.00%
終値 01/29, 16:00（ET）15分遅れの株価
46.75B時価総額
34.28直近12ヶ月PER
詳細情報 Edwards Lifesciences Corp 企業名
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corpの企業情報
企業コードEW
会社名Edwards Lifesciences Corp
上場日Mar 27, 2000
最高経営責任者「CEO」Zovighian (Bernard J)
従業員数15800
証券種類Ordinary Share
決算期末Mar 27
本社所在地One Edwards Way
都市IRVINE
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号92614
電話番号19492502500
ウェブサイトhttps://www.edwards.com
企業コードEW
上場日Mar 27, 2000
最高経営責任者「CEO」Zovighian (Bernard J)
Edwards Lifesciences Corpの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
事業別USD
会社名
収益
比率
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
地域別USD
会社名
収益
比率
United States
907.50M
58.43%
Europe
387.90M
24.98%
Rest of the world
167.60M
10.79%
Japan
90.10M
5.80%
事業別
地域別
事業別USD
会社名
収益
比率
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
株主
更新時刻: Sat, Jan 10
更新時刻: Sat, Jan 10
株主統計
種類
株主統計
株主統計
比率
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
他の
71.62%
株主統計
株主統計
比率
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
他の
71.62%
種類
株主統計
比率
Investment Advisor
46.83%
Investment Advisor/Hedge Fund
30.96%
Hedge Fund
3.47%
Pension Fund
2.27%
Research Firm
2.17%
Bank and Trust
1.96%
Sovereign Wealth Fund
1.37%
Individual Investor
0.93%
Endowment Fund
0.83%
他の
9.21%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
2452
517.66M
93.53%
--
2025Q3
2537
517.80M
94.00%
-1.50M
2025Q2
2614
519.17M
94.35%
-5.19M
2025Q1
2599
525.51M
93.66%
-25.15M
2024Q4
2585
522.16M
89.45%
+17.15M
2024Q3
2546
504.88M
87.53%
-10.03M
2024Q2
2541
515.71M
87.77%
+1.93M
2024Q1
2555
513.21M
86.74%
-8.92M
2023Q4
2556
503.19M
87.55%
-12.35M
2023Q3
2509
516.79M
88.03%
-521.37K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
The Vanguard Group, Inc.
70.09M
12.08%
+359.01K
+0.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
30.52M
5.26%
-370.16K
-1.20%
Sep 30, 2025
State Street Investment Management (US)
25.62M
4.41%
-14.75K
-0.06%
Sep 30, 2025
Wellington Management Company, LLP
20.80M
3.59%
+977.93K
+4.93%
Sep 30, 2025
JP Morgan Asset Management
17.92M
3.09%
-2.17M
-10.80%
Sep 30, 2025
Jennison Associates LLC
13.96M
2.41%
+2.29M
+19.60%
Sep 30, 2025
Fidelity Management & Research Company LLC
13.03M
2.25%
+10.73M
+466.56%
Sep 30, 2025
Geode Capital Management, L.L.C.
12.84M
2.21%
+114.73K
+0.90%
Sep 30, 2025
Walter Scott & Partners Ltd.
9.96M
1.72%
+1.05M
+11.73%
Sep 30, 2025
Union Investment Privatfonds GmbH
8.60M
1.48%
+19.17K
+0.22%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares U.S. Medical Devices ETF
4.72%
Future Fund Long/Short ETF
3.86%
iShares Health Innovation Active ETF
3.65%
Global X Aging Population ETF
3.31%
Acruence Active Hedge US Equity ETF
2.58%
First Trust Indxx Medical Devices ETF
2.23%
State Street SPDR S&P Health Care Equipment ETF
1.88%
JPMorgan Healthcare Leaders ETF
1.8%
PGIM Jennison Better Future ETF
1.78%
ROBO Global Healthcare Technology & Innovation ETF
1.73%
詳細を見る
iShares U.S. Medical Devices ETF
比率4.72%
Future Fund Long/Short ETF
比率3.86%
iShares Health Innovation Active ETF
比率3.65%
Global X Aging Population ETF
比率3.31%
Acruence Active Hedge US Equity ETF
比率2.58%
First Trust Indxx Medical Devices ETF
比率2.23%
State Street SPDR S&P Health Care Equipment ETF
比率1.88%
JPMorgan Healthcare Leaders ETF
比率1.8%
PGIM Jennison Better Future ETF
比率1.78%
ROBO Global Healthcare Technology & Innovation ETF
比率1.73%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
May 07, 2020
Split
1→3
日付
配当落ち日
種類
比率
May 07, 2020
Split
1→3
